BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:59:53 2024-05-20 pm EDT 5-day change 1st Jan Change
173.1 USD +0.14% Intraday chart for BeiGene, Ltd. +6.76% -4.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
BeiGene's Q1 Loss Narrows as Revenue Rises MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024 CI
Amgen Posts Higher 1Q Revenue, Swings to Loss DJ
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer CI
BeiGene to Award Shares Worth $15 Million to 11 Directors MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates MT
Beigene Shrinks Loss by 56% in 2023 MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading MT
BeiGene, Ltd. Announces Executive Changes CI
Beigene's Esophageal Cancer Drug Gets US FDA Nod MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients DJ
Chart BeiGene, Ltd.
More charts
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
172.8 USD
Average target price
267 USD
Spread / Average Target
+54.48%
Consensus
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.
  5. BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW